IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Pine Haven Investment Counsel Inc

Pine Haven Investment Counsel Inc raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.9% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 973 shares of the company’s stock after acquiring an additional 119 shares during the period. Pine Haven Investment Counsel Inc’s holdings in IDEXX Laboratories were worth $492,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Riverview Trust Co purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. Crewe Advisors LLC purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. Ridgewood Investments LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $28,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several research analyst reports. JPMorgan Chase & Co. decreased their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research note on Wednesday, August 14th. BTIG Research started coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Trading Up 0.8 %

NASDAQ IDXX traded up $3.70 on Friday, hitting $476.98. 145,495 shares of the company were exchanged, compared to its average volume of 465,375. The firm has a market capitalization of $39.26 billion, a P/E ratio of 47.19, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The company’s 50 day moving average price is $487.85 and its 200-day moving average price is $494.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.67 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.